Pfizer has broken ground on a research and development and process development facility in Chesterfield, Missouri.

The new campus will be owned by Pfizer and will bring together more than 450 employees who currently work at multiple locations that the company leases in the St. Louis area. Pfizer expects to hire an additional 80 employees over the coming years to support research at the site.

The facility will provide approximately 295,000 square feet of space to house Pfizer’s BioTherapeutics Pharmaceutical Sciences group and enabling partners. This team is responsible for advancing Pfizer’s biologics, vaccines, and gene therapy portfolio by developing manufacturing processes and dosage forms using analytical technologies and by conducting non-GMP manufacturing and scale-up studies.

The campus will include a floor plan that provides flexible laboratory layouts, scientific casework and utility hookups, open office and collaboration spaces, and increased conferencing technologies where researchers can collaborate.

Construction is expected to be completed by mid-2019.

The St. Louis site is an important part of Pfizer’s worldwide R&D network, which includes locations in La Jolla, California.; Pearl River, New York; Groton, Connecticut.; and Cambridge and Andover, Massachusetts.

Source: Pfizer